tiprankstipranks
Advertisement
Advertisement

Sichuan Kelun-Biotech Wins Approval for Full Circulation of Additional H Shares

Story Highlights
  • Sichuan Kelun-Biotech gained Hong Kong approval to list 8.21 million converted H shares.
  • The conversion boosts H shares to 73.32% of capital, enhancing liquidity and removing unlisted foreign shares.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sichuan Kelun-Biotech Wins Approval for Full Circulation of Additional H Shares

Meet Samuel – Your Personal Investing Prophet

The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, focuses on raising capital through H shares alongside domestic and foreign share classes. Its stock structure includes a significant portion of H shares, which are tradable on the Hong Kong Stock Exchange and form the primary channel for international investors.

The company has received approval from the Hong Kong Stock Exchange to list 8,214,278 converted H shares under its H Share Full Circulation plan. Following the conversion of domestic and unlisted foreign shares into H shares, H shares will rise to 73.32% of total share capital, domestic shares will fall to 26.68%, and unlisted foreign shares will be eliminated, increasing market liquidity and aligning its capital structure more closely with international trading practices.

The company will now proceed with the technical conversion and trading procedures needed to complete the listing of the converted H shares. It has indicated that further updates will be provided as the process advances, while advising shareholders and potential investors to exercise caution when dealing in its securities during the transition period.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$526.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company incorporated in the People’s Republic of China. The company issues H shares on the Hong Kong Stock Exchange, with its share capital structure comprising H shares, domestic shares and, until now, unlisted foreign shares.

Average Trading Volume: 530,394

Technical Sentiment Signal: Buy

Current Market Cap: HK$117.4B

For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1